Compare Cardinal Health Inc (CAH) vs Freeport-McMoRan Inc (FCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Freeport-McMoRan Inc — how do they compare? Cardinal Health Inc trades at $224.88 (market cap $53.89B), while Freeport-McMoRan Inc trades at $61.02 (market cap $89.06B). The key difference: Freeport-McMoRan Inc is the larger of the two by market cap, and Freeport-McMoRan Inc pays the higher dividend (0.97%). Which is the better fit depends on your goals.
| CAH | FCX | |
|---|---|---|
Market Cap | $53.89B | $89.06B |
Sector | Health | Basic Materials |
52-Week High | $239.71 | $71.73 |
52-Week Low | $146.04 | $35.34 |
Enterprise Value | $58.87B | $95.72B |
Dividend Yield | 0.89% | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
FCX trades at $59.98, down 2.51% today, with a bearish technical signal but strong fundamentals. Recent earnings beats and a 10.34% net income margin highlight operational strength. The stock faces near-term resistance at $61, with support at $59. Analysts maintain a $72.94 consensus target, reflecting 22% upside potential. Copper demand growth and expansion projects support long-term prospects.
Outlook remains positive driven by copper's structural supply-demand imbalance and FCX's cost leadership. Risks include commodity price volatility and execution challenges in new projects. Institutional sentiment is bullish with 59% buy ratings, though technical indicators suggest near-term consolidation. The dividend yield of 0.25% provides modest income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →
